Clopidogrel/aspirin - Chong Kun Dang

Drug Profile

Clopidogrel/aspirin - Chong Kun Dang

Alternative Names: Aspirin/clopidogrel - Chong Kun Dang; Coprigrel

Latest Information Update: 22 Apr 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chong Kun Dang
  • Class Antiplatelets; Antipyretics; Pyridines; Salicylic acids; Small molecules; Thienopyridines
  • Mechanism of Action Cyclooxygenase inhibitors; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Coronary artery disease

Most Recent Events

  • 09 Mar 2013 Pharmacokinetics and adverse events data from a Phase-I trial in Coronary artery disease (in volunteers) presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2013)
  • 01 Sep 2011 Phase-I development is ongoing in South Korea
  • 01 Dec 2010 Phase-I clinical trials in Coronary artery disease in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top